An investment firm founded in 2015 invests in technology, medical, and science-related deals. The firm typically engages in late Seed and Series A financings with typical check size being around $2M. Though the firm’s first searches are in the Midwest US, they are open to all investment opportunities across the US – generally, the firm avoids Boston and Silicon Valley. The firm will lead about half of its investments.
Within life sciences, the firm invests in all sectors but is currently focusing on therapeutics and diagnostics companies. The firm is generally indication-agnostic, but in terms of diagnostics, they are focusing on cancer. For therapeutics companies, the firm prefers them to be about a year before conducting human trials. For medical devices, diagnostics, and digital health, companies should be pre-revenue and pre-FDA approval.
The firm does not require to take a board observer seat but may take one depending on the case.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment